Skip to content

SPRING PHARMACEUTICAL GROUP, INC.: 10-Q filed 2017-02-13

What SPRING PHARMACEUTICAL GROUP, INC. reported in its quarterly report filed 2017-02-13 (fiscal Q3 2017): 30 published measures, 82 facts as tagged in accession 0001096906-17-000084.

This filing

Form
10-Q (quarterly report)
Filed
2017-02-13
Fiscal period
fiscal Q3 2017
Accession
0001096906-17-000084 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All SPRING PHARMACEUTICAL GROUP, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-12-3182,446,764USD
At 2016-03-3181,315,507USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-12-3180,873,466USD
At 2016-03-3180,349,551USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-12-319,784,431USD
At 2016-03-317,639,084USD
At 2015-12-314,749,825USD
At 2015-03-3113,083,532USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-10-01 to 2016-12-312,588,165USD92
2016-04-01 to 2016-12-316,159,400USD275
2015-10-01 to 2015-12-311,838,689USD92
2015-04-01 to 2015-12-318,012,897USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-04-01 to 2016-12-317,283,144USD275
2015-04-01 to 2015-12-315,418,101USD275

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-04-01 to 2016-12-311,374,790USD275
2015-04-01 to 2015-12-311,278,362USD275

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-10-01 to 2016-12-3114,171,624USD92
2016-04-01 to 2016-12-3135,478,603USD275
2015-10-01 to 2015-12-3111,858,027USD92
2015-04-01 to 2015-12-3137,467,517USD275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2016-04-01 to 2016-12-31-4,508,068USD275
2015-04-01 to 2015-12-31-13,333,542USD275

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-10-01 to 2016-12-31849,716USD92
2016-04-01 to 2016-12-312,078,344USD275
2015-10-01 to 2015-12-31562,081USD92
2015-04-01 to 2015-12-312,598,051USD275

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-12-3112,798,969USD
At 2016-03-3112,872,997USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-10-01 to 2016-12-313,426,808USD92
2016-04-01 to 2016-12-318,194,522USD275
2015-10-01 to 2015-12-312,396,755USD92
2015-04-01 to 2015-12-3110,585,328USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-12-3114,991,591USD
At 2016-03-3111,421,267USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-12-311,573,298USD
At 2016-03-31965,956USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2016-12-31506,196USD
At 2016-03-31533,262USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-10-01 to 2016-12-312,386,693USD92
2016-04-01 to 2016-12-316,002,131USD275
2015-10-01 to 2015-12-312,679,626USD92
2015-04-01 to 2015-12-316,396,235USD275

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2016-12-313,805,311USD
At 2016-03-312,287,312USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2016-10-01 to 2016-12-315,813,501USD92
2016-04-01 to 2016-12-3114,196,653USD275
2015-10-01 to 2015-12-315,076,381USD92
2015-04-01 to 2015-12-3116,981,563USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-10-01 to 2016-12-31279,589USD92
2016-04-01 to 2016-12-31754,485USD275
2015-10-01 to 2015-12-31247,259USD92
2015-04-01 to 2015-12-31659,836USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-12-3129,764,168shares
At 2016-03-3129,720,690shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2016-12-31-4,910,056USD
At 2016-03-31837,064USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2016-12-3116,291,993USD
At 2016-03-3116,070,702USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2016-12-31-3,493,024USD
At 2016-03-31-3,197,705USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2016-12-3110,652,515USD
At 2016-03-3112,295,147USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-508,648USD92
2016-04-01 to 2016-12-31412,280USD275
2015-10-01 to 2015-12-31219,449USD92
2015-04-01 to 2015-12-313,628,416USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-10-01 to 2016-12-311,137,609USD92
2016-04-01 to 2016-12-312,722,468USD275
2015-10-01 to 2015-12-311,014,651USD92
2015-04-01 to 2015-12-312,645,877USD275

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2016-10-01 to 2016-12-31176,755USD92
2016-04-01 to 2016-12-31534,567USD275
2015-10-01 to 2015-12-31153,963USD92
2015-04-01 to 2015-12-31468,176USD275

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2016-04-01 to 2016-12-31-830,262USD275
2015-04-01 to 2015-12-31-987,504USD275

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2016-04-01 to 2016-12-31-10,893USD275
2015-04-01 to 2015-12-31-39,919USD275

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-12-31-9,878USD275
2015-04-01 to 2015-12-31-155,530USD275

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-12-31-1,739,711USD275
2015-04-01 to 2015-12-31-2,399,986USD275

Inspect the source

Entity
SPRING PHARMACEUTICAL GROUP, INC. / CIK 0000847464
Captured
SEC response SHA-256
21fd63bfa4a441f5dd22dbcc8093e88a40c5d63950c8b6833c77a7b4245f4dc7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000847464.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))